ATG5 and metabolic dysfunction-associated steatotic liver disease: The findings of our investigation indicate that DHM administration resulted in a dose-dependent increase in the expression of autophagy markers, specially Beclin1, ATG5, and LC3-II, in both a rat model of NAFLD and a cellular model of hepatocytic steatosis.